Tata India Pharma and Healthcare Fund
Direct · GrowthAI Summary
Tata India Pharma and Healthcare Fund has delivered strong SIP XIRR of 21.15% over 3Y and 21.46% over 5Y, outperforming the category average SIP XIRR of 16.82% and 16.95% respectively. However, its 1Y XIRR of 10.76% trails the category average of 14.1%, reflecting recent sector softness. Against the NIFTY 50, the fund has generated consistent alpha across horizons, including 13.23% over 3Y and 13.91% over 7Y.
The fund exhibits low beta of roughly 0.51-0.59 versus the NIFTY 50, with downside capture consistently below 52% across all horizons, indicating it has historically fallen far less than the benchmark in weak markets. It has experienced 5 drawdown events exceeding 10%, with a maximum drawdown duration of 567 days and a recovery period of 375 days, underscoring the patience required through sector cycles. Calmar ratios between 0.71 and 0.95 across horizons suggest reasonable risk-adjusted returns relative to drawdown depth.
The portfolio holds 34 stocks with the top 10 accounting for roughly 47% of NAV, led by Sun Pharmaceutical at 8.51% and Max Healthcare at 5.68%. Sector exposure is heavily concentrated in Pharmaceuticals & Biotechnology at 59.7% and Healthcare Services at 32.3%, with a meaningful tilt toward hospitals and healthcare delivery alongside traditional pharma. This concentrated, sector-specific structure is inherent to the thematic mandate and limits diversification benefits.
The fund has beaten the category average SIP XIRR over 3Y, 5Y, 7Y, and 10Y windows, with the widest gap of over 4 percentage points in the 3Y and 5Y periods. Its calendar year returns show strong consistency in favorable years, such as 66.78% in 2020 and 42.01% in 2024, though it has posted negative years in 2016, 2022, and 2025. This pattern reflects typical sectoral cyclicality rather than fund-specific weakness.
This fund is suitable for investors with high risk tolerance who already hold a diversified core portfolio and want a tactical healthcare allocation. A horizon of at least 5-7 years is advisable, given the multi-year drawdown and recovery periods observed and the sector's cyclical nature. Investors should size the position modestly, as thematic funds can underperform the broader market for extended stretches.
- Consistent alpha versus NIFTY 50 across all measured horizons, ranging from 2.44% over 15Y to 13.91% over 7Y
- Low downside capture of 41-52% across horizons, limiting losses relative to the benchmark in falling markets
- SIP XIRR above category averages over 3Y, 5Y, 7Y, and 10Y periods, including 21.46% over 5Y versus 16.95% for the category
- Heavy sector concentration with 92% of the portfolio in just two sectors, exposing investors to healthcare-specific downturns
- 1Y XIRR of 10.76% trails the category average of 14.1%, and the fund posted a -3.8% return in 2025, indicating current momentum has cooled
- Extended drawdown behavior, with a maximum drawdown lasting 567 days and taking 375 days to recover
Generated on 06-09-2026, 7:51 PM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.42 L | 17.1% | -24.2% | 89.8% |
| 3 Years | ₹36.00 L | ₹46.76 L | 19.6% | -2.5% | 41.5% |
| 5 Years | ₹60.00 L | ₹99.46 L | 21.2% | 12.6% | 31.3% |
| 7 Years | ₹84.00 L | ₹1.76 Cr | 20.5% | 11.9% | 27.8% |
| 10 Years | ₹1.20 Cr | ₹3.10 Cr | 18.2% | 16.4% | 19.4% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 17.1% | 14.4% | 14.1% | +2.7% |
| 3 Years | 19.6% | 11.1% | 16.8% | +8.5% |
| 5 Years | 21.2% | 10.4% | 16.9% | +10.8% |
| 7 Years | 20.5% | 10.6% | 16.5% | +9.9% |
| 10 Years | 18.2% | 11.5% | 16.7% | +6.7% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 16.7% | 8.8% | -17.3% | 76.3% | 0.46 | 1.52 | 70% | — | — |
| 3 Years | 18.2% | 21.3% | -3.4% | 30.5% | 1.30 | 4.31 | 91% | — | — |
| 5 Years | 18.9% | 16.8% | 9.3% | 31.6% | 2.32 | — | 100% | — | — |
| 10 Years | 14.1% | 13.9% | 12.6% | 15.3% | 10.36 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +8.50 | 0.57 | 63.1% | 48.7% | 9.6% | -2.9% |
| 3 Years | +13.23 | 0.58 | 70.4% | 51.0% | 20.5% | 7.8% |
| 5 Years | +7.93 | 0.56 | 61.5% | 48.4% | 15.2% | 7.8% |
| 7 Years | +13.91 | 0.51 | 58.7% | 41.5% | 23.1% | 11.8% |
| 10 Years | +6.25 | 0.54 | 60.7% | 50.2% | 15.1% | 10.8% |
| 12 Years | +3.89 | 0.55 | 60.5% | 51.7% | 12.2% | 9.8% |
| 15 Years | +2.44 | 0.55 | 60.5% | 51.7% | 9.6% | 7.7% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LTD | 8.51% |
| 2 | MAX HEALTHCARE INSTITUTE LTD | 5.68% |
| 3 | HEALTHCARE GLOBAL ENTERPRISES LTD | 5.52% |
| 4 | DIVI LABORATORIES LTD | 5.12% |
| 5 | ABBOTT INDIA LTD | 4.97% |
| 6 | CIPLA LTD | 4.77% |
| 7 | APOLLO HOSPITALS ENTERPRISE LTD | 4.61% |
| 8 | RAINBOW CHILDRENS MEDICARE LTD | 4.42% |
| 9 | DR REDDYS LABORATORIES LTD | 4.26% |
| 10 | GLAXOSMITHKLINE PHARMACEUTICALS LTD | 4.12% |